A pharmaceutical industry perspective on microphysiological kidney systems for evaluation of safety for new therapies-Reference-Cited by-同舟云学术

A pharmaceutical industry perspective on microphysiological kidney systems for evaluation of safety for new therapies

Published:2020 Issue:3 Volume:20 Page:468-476
ISSN:1473-0197
Container-title:Lab on a Chip
language:en
Short-container-title:Lab Chip

Author:

Phillips Jonathan A.¹²³^ORCID,Grandhi Taraka Sai Pavan⁴⁵³,Davis Myrtle⁶⁷³,Gautier Jean-Charles⁸⁹¹⁰,Hariparsad Niresh¹²³,Keller Douglas¹¹¹²³^ORCID,Sura Radhakrishna¹³¹⁴¹⁵³,Van Vleet Terry R.¹³¹⁴¹⁵³

Affiliation:

1. Vertex Pharmaceuticals

2. Boston

3. USA

4. The Genomics Institute of the Novartis Research Foundation

5. San Diego

6. Bristol-Myers Squibb Company

7. Princeton

8. Sanofi R&D

9. 94400 Vitry-sur-Seine

10. France

11. Sanofi US

12. Bridgewater

13. Preclinical Safety

14. AbbVie

15. N Chicago

Abstract

The human kidney contains approximately one million nephrons.

Publisher

Royal Society of Chemistry (RSC)

Subject

Biomedical Engineering,General Chemistry,Biochemistry,Bioengineering

Link

http://pubs.rsc.org/en/content/articlepdf/2020/LC/C9LC00925F

Reference100 articles.

1. An analysis of the attrition of drug candidates from four major pharmaceutical companies

2. Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database

3. Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals

4. Generation of nephron progenitor cells and kidney organoids from human pluripotent stem cells

5. CRISPR Gene Editing in the Kidney

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bridging barriers: advances and challenges in modeling biological barriers and measuring barrier integrity in organ-on-chip systems;Lab on a Chip;2024

2. Towards in vitro models for reducing or replacing the use of animals in drug testing;Nature Biomedical Engineering;2023-12-27

3. The Current Status and Use of Microphysiological Systems by the Pharmaceutical Industry: The IQ Microphysiological Systems Affiliate Survey and Commentary;Drug Metabolism and Disposition;2023-12-12

4. Culturing the unculturables: strategies, challenges, and opportunities for gut microbiome study;Journal of Applied Microbiology;2023-11-24

5. Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) Workshop on the Standardization of Complex In Vitro Models in Drug Development;Advanced Biology;2023-10-09